Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
In a real-world ES-SCLC cohort treated with atezolizumab plus chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response.
In a real-world ES-SCLC cohort treated with atezolizumab plus chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response.
In patients with extensive-stage small cell lung cancer, concurrent radiotherapy during tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression.
In patients with extensive-stage small cell lung cancer, concurrent radiotherapy during tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression.
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
